News | March 23, 2026
Zydus launches affordable Semaglutide in India after patent expiry
Targets diabetes & obesity crisis as India grapples with soaring metabolic disorders
Targets diabetes & obesity crisis as India grapples with soaring metabolic disorders
The patent protects antiviral compounds developed by the company that inhibit Vacuolar ATPase (V-ATPase) activity in cells, a mechanism involved in viral infection pathways
Vapendavir is an oral, potent, broad-spectrum antiviral active against rhinoviruses and related respiratory enteroviruses
The company, part of pharma powerhouse AbbVie, will showcase the findings—and the next evolution of its AA Signature framework—at AMWC 2026 in Monaco,
Esprit is a multicenter, randomized, placebo-controlled, double-blind study assessing the safety, pharmacodynamics, and preliminary efficacy of S-606001 as a substrate reduction therapy
India faces a significant and growing burden of chronic respiratory diseases such as asthma, chronic obstructive pulmonary disease
The initial consideration for the transaction is US$ 12 million
The planned facility, to be built at Samsung’s Bio Campus II, is set to become a launchpad for up to 30 emerging biotech firms
The Taipei facility boasts 10 GMP API production lines, with a total reactor volume exceeding 350,000 liters
The trial will enroll up to 42 patients in Finland across four cohorts
Subscribe To Our Newsletter & Stay Updated
